Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NB Clear all
Terminated Not applicable Interventional

Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

NCT00844363
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
NB-UVB
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 26, 2026, 1:29 PM EDT
Terminated Not applicable Interventional

Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

NCT05238077
View directory record Official record
Conditions
Generalized Vitiligo
Interventions
Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

NCT02100930
View directory record Official record
Conditions
Neuroblastoma
Interventions
Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

Psoriasis Microbiome and Phototherapy

NCT02552316
View directory record Official record
Conditions
Psoriasis
Interventions
NB-UVB Phototherapy
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

NCT02348749
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
18F-MFBG (meta-fluoro benzylguanidine), Positron emission tomography (PET) imaging, Blood draws
Radiation · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
5 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 26, 2026, 1:29 PM EDT
Withdrawn No phase listed Observational

Airway Inflammatory Response During Illness in Children With Respiratory Failure

NCT02047877
View directory record Official record
Conditions
Acute Respiratory Failure, Acute Respiratory Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 26, 2026, 1:29 PM EDT
Completed No phase listed Observational

Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

NCT01451879
View directory record Official record
Conditions
Pompe Disease
Interventions
Rituximab, Miglustat
Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 26, 2026, 1:29 PM EDT
Suspended Early Phase 1 Interventional

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

NCT06235281
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Mogamulizumab-Kpkc, Phototherapy
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

NCT01114555
View directory record Official record
Conditions
Neuroblastoma
Interventions
Bevacizumab, Irinotecan and Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 26, 2026, 1:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

NCT06109649
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide and NB-UVB Light, NB-UVB Light
Drug · Procedure
Lead sponsor
Clinuvel, Inc.
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
25
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 4 Interventional

NB-UVB and PUVA Vitiligo Study

NCT01732965
View directory record Official record
Conditions
Vitiligo
Interventions
Phototherapy, Phototherapy and Photochemotherapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

NCT03270241
View directory record Official record
Conditions
Vitiligo, Dermatology/Skin - Other
Interventions
Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 26, 2026, 1:29 PM EDT
Terminated Not applicable Interventional Results available

Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo

NCT02506101
View directory record Official record
Conditions
Vitiligo, Pigmentation, Dyschromia
Interventions
narrow-band ultraviolet B phototherapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 26, 2026, 1:29 PM EDT
Active, not recruiting Phase 1 Interventional

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT02359565
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
Interventions
Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

NCT03539900
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 26, 2026, 1:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Food Form on Cephalic Phase Responses

NCT01550133
View directory record Official record
Conditions
Obese, Overweight
Interventions
Learned: Non-nutritive beverage to Non-nutritive beverage, Learned: Nutritive solid to Nutritive solid, Learned: Nutritive beverage to Nutritive beverage, Not Learned: Non-nutritive solid to Nutritive solid, Not Learned: Nutritive beverage to Non-nutritive beverage, Not Learned: Non-Nutritive solid to Non-Nutritive Solid, Not Learned: Non-nutritive beverage to Nutritive beverage
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 1 Interventional

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT00877110
View directory record Official record
Conditions
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Interventions
cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 26, 2026, 1:29 PM EDT
Recruiting Phase 2 Interventional

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948
View directory record Official record
Conditions
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions
OPT-821 (QS-21), oral β-glucan
Biological · Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

NCT02748317
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Lactobacillus rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 26, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

NCT02107482
View directory record Official record
Conditions
Psoriasis
Interventions
Levia Narrow Band UVB, Levia sham/visible-light source
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 26, 2026, 1:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

NCT01757626
View directory record Official record
Conditions
Neuroblastoma
Interventions
Hu3F8 With GM-CSF
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 26, 2026, 1:29 PM EDT